1Seybert AL. Bivalirudin administration during percutaneous coronary intervention: emphasis on high-risk patients. Pharmacotherapy, 2002, 22(6 Pt 2): 112S-118S.
2Wittkowsky AK. The role of thrombin inhibition during percutaneous coronary intervention. Pharmacotherapy, 2002,22(6 Pt 2) :97S-104S.
3Stella JF,Stella RE,Iaffaldano Affaldano RA,et al. Anticoagulation with bivalirudin during percutaneous coronary intervention for ST-segment elevation myocardial infarction. J lnvasive Cardiol, 2004, 16(9): 451-454.
4Mahffey KW, Lewis BE, Wildermann NM, et al. The anlicoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with hepafin-induced thrombocytopenia (ATBAT) study: main resuhs. J Invasive Cardiol, 2003,15(11):611-616.
5Chew DP, Lincoff AM, Gurm H, et al. Bivalirudin versus heparin and glycoprotein Ⅱ b /Ⅲ a inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). Am J Cardiol,2005,95(5):581-585.
6Caron MF, Mckendall GR. Bivalirudin in percutaneous coronary intervention. Am J Health Syst Pharm,2003,60(18): 1841-1849.
